CEL-SCI Corporation Reports Second Quarter 2012 Financial Results

CEL-SCI Corporation (NYSE AMEX: CVM) announced today financial results for the fiscal quarter ended March 31, 2012.

CEL-SCI reported that net loss available to common shareholders for the quarter ended March 31, 2012 was $(10,086,959) versus $(15,097,973) during the same quarter ended March 31, 2011. Net loss per common share, (basic) was $(0.04) for the quarter ended March 31, 2012 versus $(0.07) during the same quarter ended March 31, 2011. The operating loss for the quarter ended March 31, 2012 was $(4,262,357) versus $(5,096,996) during the same quarter ended March 31, 2011. Net loss available to common shareholders for the six months ended March 31, 2012 was $(14,243,792) versus $(21,348,925) million during the same six months ended March 31, 2011. Net loss per common share, (basic) was $(0.06) for the six months ended March 31, 2012 versus $($0.10) during the same six months ended March 31, 2011. The operating loss for the six months ended March 31, 2012 was $(8,705,633) versus $(9,413,030) during the same six months ended March 31, 2011.

R&D expenses for the quarter ended March 31, 2012 totaled $2,594,235 versus R&D expenses of $3,042,097 for the quarter ended March 31, 2011. R&D expenses for the six months ended March 31, 2012 totaled $5,050,420 versus R&D expenses of $6,306,525 for the six months ended March 31, 2011. R&D expenses related to the running of the Company’s Phase III clinical trial declined because of lower Multikine manufacturing expenditures and lower costs related to the set-up of the clinical sites that had been present in the same period last year.

Geert Kersten, Chief Executive Officer, said, “Our global Phase III clinical trial for our investigational cancer drug Multikine is moving forward as anticipated. We continue to believe that we will end up being successful in this trial and that we will develop a paradigm shift in the way that head and neck cancer is treated.”

If you liked this article you might like

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

4 Stocks Under $10 Making Big Moves Higher

Cel-Sci's Enrollment Math Doesn't Add up